STOCK TITAN

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Annexon, Inc. (Nasdaq: ANNX) announced the granting of equity inducement awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. The awards, approved on October 17, 2022, involve options to purchase 87,400 shares of common stock, with an exercise price of $5.63 per share, reflecting the closing stock price on the grant date. The options have a ten-year term and vest over four years. Annexon focuses on developing complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders.

Loading...
Loading translation...

Positive

  • Equity awards may enhance employee retention and motivation.
  • Options to purchase 87,400 shares could align employee interests with company performance.
  • The exercise price of $5.63 is in line with the stock's recent closing price.

Negative

  • None.
Argus Session date unavailable
-6.75% session move Open Argus
Details

News Market Reaction – ANNX

The recorded move for ANNX in the trading session of this news was -6.75%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BRISBANE, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on October 17, 2022, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the new non-executive employees received options to purchase 87,400 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $5.63, which was the closing price of Annexon’s common stock on October 17, 2022, the date of grant, and vest over four years, with 25% of the shares underlying the options vesting on the first anniversary of each employee’s employment start date, and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.  

About Annexon

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company that aims to bring game-changing medicines to patients with classical complement-mediated diseases of the body, brain and eye. The classical complement cascade is a seminal pathway within the immune system that anchors and drives a host of autoimmune, neurodegenerative and ophthalmic diseases. Annexon is advancing a new class of complement medicines targeting the early classical cascade and all downstream pathway components that contribute to disease, while selectively preserving the beneficial immune functions of other complement pathways. Annexon is rigorously developing a pipeline of diversified product candidates across multiple mid- to late-stage clinical trials, with clinical data anticipated throughout 2022 and 2023.

Investor Contact:

Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the significance of Annexon's equity inducement awards announced on October 18, 2022?

The equity inducement awards are aimed at motivating new non-executive employees, potentially enhancing retention and aligning their interests with the company's performance.

How many shares were awarded to employees by Annexon on October 17, 2022?

Annexon granted options to purchase a total of 87,400 shares of common stock to three new non-executive employees.

What is the exercise price for the equity options granted by Annexon?

The exercise price for the options is $5.63 per share, which corresponds to the company's closing stock price on the grant date, October 17, 2022.

What is the vesting schedule for the equity awards granted by Annexon?

The options vest over four years, with 25% vesting on the first anniversary of each employee's start date and the remaining shares vesting monthly thereafter.

Keep reading